Literature DB >> 10604473

Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons.

J A Bibb1, G L Snyder, A Nishi, Z Yan, L Meijer, A A Fienberg, L H Tsai, Y T Kwon, J A Girault, A J Czernik, R L Huganir, H C Hemmings, A C Nairn, P Greengard.   

Abstract

The physiological state of the cell is controlled by signal transduction mechanisms which regulate the balance between protein kinase and protein phosphatase activities. Here we report that a single protein can, depending on which particular amino-acid residue is phosphorylated, function either as a kinase or phosphatase inhibitor. DARPP-32 (dopamine and cyclic AMP-regulated phospho-protein, relative molecular mass 32,000) is converted into an inhibitor of protein phosphatase 1 when it is phosphorylated by protein kinase A (PKA) at threonine 34. We find that DARPP-32 is converted into an inhibitor of PKA when phosphorylated at threonine 75 by cyclin-dependent kinase 5 (Cdk5). Cdk5 phosphorylates DARPP-32 in vitro and in intact brain cells. Phospho-Thr 75 DARPP-32 inhibits PKA in vitro by a competitive mechanism. Decreasing phospho-Thr 75 DARPP-32 in striatal slices, either by a Cdk5-specific inhibitor or by using genetically altered mice, results in increased dopamine-induced phosphorylation of PKA substrates and augmented peak voltage-gated calcium currents. Thus DARPP-32 is a bifunctional signal transduction molecule which, by distinct mechanisms, controls a serine/threonine kinase and a serine/threonine phosphatase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604473     DOI: 10.1038/45251

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  201 in total

1.  Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo.

Authors:  G L Snyder; P B Allen; A A Fienberg; C G Valle; R L Huganir; A C Nairn; P Greengard
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

Review 2.  DeltaFosB: a sustained molecular switch for addiction.

Authors:  E J Nestler; M Barrot; D W Self
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

3.  Switching between the two action modes of the dual-affinity nitrate transporter CHL1 by phosphorylation.

Authors:  Kun-Hsiang Liu; Yi-Fang Tsay
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

4.  Integrin alpha(1) beta(1)-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation.

Authors:  B S Li; L Zhang; J Gu; N D Amin; H C Pant
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

5.  Activation of Aurora-A kinase by protein phosphatase inhibitor-2, a bifunctional signaling protein.

Authors:  David L Satinover; Craig A Leach; P Todd Stukenberg; David L Brautigan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

6.  Nerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brain.

Authors:  Hongwen Zhu; Jennifer J O'Brien; James P O'Callaghan; Diane B Miller; Qiang Zhang; Minal Rana; Tiffany Tsui; Youyi Peng; John Tomesch; Joseph P Hendrick; Lawrence P Wennogle; Gretchen L Snyder
Journal:  Brain Res       Date:  2010-04-25       Impact factor: 3.252

Review 7.  Activation of progestin receptors in female reproductive behavior: Interactions with neurotransmitters.

Authors:  Shaila Mani; Wendy Portillo
Journal:  Front Neuroendocrinol       Date:  2010-01-29       Impact factor: 8.606

8.  t-Darpp stimulates protein kinase A activity by forming a complex with its RI regulatory subunit.

Authors:  Dirk Theile; Shuhui Geng; Erin C Denny; Jamil Momand; Susan E Kane
Journal:  Cell Signal       Date:  2017-09-01       Impact factor: 4.315

9.  Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs.

Authors:  L J Hampson; P Mackin; L Agius
Journal:  Diabetologia       Date:  2007-06-20       Impact factor: 10.122

10.  Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease.

Authors:  Patrice D Smith; Stephen J Crocker; Vernice Jackson-Lewis; Kelly L Jordan-Sciutto; Shawn Hayley; Matthew P Mount; Michael J O'Hare; Steven Callaghan; Ruth S Slack; Serge Przedborski; Hymie Anisman; David S Park
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.